Sorry, you need to enable JavaScript to visit this website.
Skip to main content

This site is intended for US healthcare professionals only.

This site is intended for US healthcare professionals only.

Dosing that won’t disrupt your patient’s lifestyle1

Dosing that
won’t disrupt
your patient’s lifestyle1

1 day

The recommended dose is 300 mg (2 tablets of 150 mg), twice a day for one day (BID)1

Image of BREXAFEMME® (ibrexafungerp tablets) pill packet

If possible, each dose should be taken 12 hours apart. Instruct patients to1:

  • Icon of a sun

    Take two tablets in the morning

  • Icon of a crescent moon

    Take two tablets in the evening

  • BREXAFEMME may be taken with or without food.1
  • Prior to initiating treatment, verify pregnancy status in females of reproductive potential.1

Image of BREXAFEMME® (ibrexafungerp tablets) pill packet

SAY NO MORE to vaginal yeast infections. Prescribe BREXAFEMME today.

SAY NO MORE to vaginal yeast infections.
Prescribe BREXAFEMME today.

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References

1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Data on file. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

/ / / /
  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

Read full Important Safety Information